medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Número 6

<< Anterior Siguiente >>

Ann Hepatol 2016; 15 (6)


Hepatoportal sclerosis related to the use of herbal and nutritional supplements. Causality or coincidence?

Ferreira RF, Rodrigues FLA, Codes L, Oliveira SJG, Schinoni MI, Paraná R

Idioma: Ingles.
Referencias bibliográficas: 43
Paginas: 932-938
Archivo PDF: 238.26 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Garcia-Pagan JC, Groszmann R, Bosch J. Portal hypertension. In: Weinstein WM, Hawkey CJ, Bosch J (Eds.). Portal hypertension. 1st. ed. Philadelphia: Elsevier Mosby; 2005, p. 707-16.

  2. Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011; 54: 1071-81.

  3. De Cock KM. Hepatosplenic schistosomiasis: a clinical review. Gut 1986; 27: 734-45.

  4. Bittencourt PL, Couto CA, Ribeiro DD. Portal vein thrombosis and budd-Chiari syndrome. Hematol Oncol Clin North Am 2011; 25: 1049-66.

  5. Dunn MA, Kamel R. Hepatic schistosomiasis. Hepatology 1981; 1: 653-61.

  6. Ministério da Saúde. Esquistossomose Mansônica. Guia de Vigilância Epidemiológica. Brasília: Fundo Nacional Saúde. Ministério da Saúde; 2009.

  7. Garcia-Pagán JC, Hernández-Guerra M, Bosch J. Extrahepatic portal vein thrombosis. Semin Liver Dis 2008; 28: 282-92.

  8. Datta DV. Non-cirrhotic portal fibrosis (idiopathic portal hypertension) in India. J Assoc Physicians India 1976; 24: 511-27.

  9. Kobayashi Y, Inokuchi K, Saku M. Epidemiology of idiopathic portal hypertension based on a nation-wide survey. In: Suguira M (Ed.). Report of the ministry of health and welfare research committee on idiopathic portal hypertension. Tokyo: Japan Ministry of Health and Welfare; 1976: 10-5.

  10. Mikkelsen WP, Edmondson HA, Peters RL, Redeker AG, Reynolds TB. Extra- and intrahepatic portal hypertension without cirrhosis (hepatoportal sclerosis). Ann Surg 1965; 162: 602-20.

  11. Aggarwal S, Fiel MI, Schiano TD. Obliterative portal venopathy: a clinical and histopathological review. Dig Dis Sci 2013; 58: 2767-76.

  12. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006; 44: 7-14.

  13. Nakanuma Y, Kouda W, Nakano T, Uneno K, Tachibana S, Araki I. A case report of early idiopathic portal hypertension. Pathol Res Pract 2001; 197: 759-63.

  14. Nayak NC, Ramalingaswami V. Obliterative portal venopathy of the liver. Associated with so-called idiopathic portal hypertension or tropical splenomegaly. Arch Pathol 1969; 87: 359-69.

  15. Elinav E, Pinsker G, Safadi R, Pappo O, Bromberg M, Anis E, Keinan-Boker L, et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol 2007; 47: 514-20.

  16. Stickel F, Shouval D. Hepatotoxicity of herbal and dietary supplements: an update. Arch Toxicol 2015; 89: 851-65.

  17. Strader DB, Seeff LB. Zakim and Boyer hepatology. In: Boyer TD, Wright TL, Manns MP (Eds.). Hepatotoxicity of herbal preparations. 5th ed. Philadelphia: US Saunders – Elsevier; 2006, p. 551-60.

  18. Shad JA, Chinn CG, Brann OS. Acute hepatitis after ingestion of herbs. South Med J 1999; 92: 1095-7.

  19. Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 2002; 177: 440-3.

  20. Stickel F. Slimming at all costs: Herbalife-induced liver injury. J Hepatol 2007; 47(4): 444-6.

  21. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 68-9.

  22. Andrade RJ, Lucena MI, Kaplowitz N, García-Munoz B, Borraz Y, Pachkoria K, García Cortés M, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 2006; 44: 1581-8.

  23. Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. J Gastroenterol Hepatol 2002; 17: 526-34.

  24. Andrade RJ, Robles M, Fernández-Castañer A, López- Ortega S, López-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007; 13: 329-40.

  25. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66: 758-66.

  26. Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, Reichen J, Zimmermann A, et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol 2007; 47: 521-6.

  27. Duque JM, Ferreiro J, Salgueiro E, Manso G. Hepatotoxicity associated with the consumption of herbal slimming products. Med Clin (Barc) 2007; 128: 238-9.

  28. Chao S, Anders M, Turbay M, Olaiz E, Mc Cormack L, Mastai R. Toxic hepatitis by consumption Herbalife products a case report. Acta Gastroenterol Latinoam 2008; 38: 274-7.

  29. Stickel F, Droz S, Patsenker E, Bögli-Stuber K, Aebi B, Leib SL. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J Hepatol 2009; 50: 111-7.

  30. Jóhannsson M, Ormarsdóttir S, Olafsson S. Hepatotoxicity associated with the use of Herbalife. Laeknabladid 2010; 96: 167-72.

  31. Manso G, López-Rivas L, Salgueiro ME, Duque JM, Jimeno FJ, Andrade RJ, Lucena MI. Continuous reporting of new cases in Spain supports the relationship between Herbalife ® products and liver injury. Pharmacoepidemiol Drug Saf 2011; 20: 1080-7.

  32. Weston CF, Cooper BT, Davies JD, Levine DF. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J (Clin Res Ed) 1987; 295: 183.

  33. Ridker PM, Ohkuma S, McDermott WV, Trey C, Huxtable RJ. Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985; 88: 1050-4.

  34. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27-42.

  35. Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 2005; 11: 627-34.

  36. Nakanuma Y, Hoso M, Sasaki M, Terada T, Katayanagi K, Nonomura A, Kurumaya H, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996; 28: 195-204.

  37. Roskams T, Baptista A, Bianchi L, Burt A, Callea F, Denk H, De Groote J, et al. Histopathology of portal hypertension: a practical guideline. Histopathology 2003; 42: 2-13.

  38. Dhiman RK, Chawla Y, Vasishta RK, Kakkar N, Dilawari JB, Trehan MS, Puri P, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol 2002; 17: 6-16.

  39. Oikawa H, Masuda T, Sato S, Yashima A, Suzuki K, Satodate R. Changes in lymph vessels and portal veins in the portal tract of patients with idiopathic portal hypertension: a morphometric study. Hepatology 1998; 27: 1607-10.

  40. Villeneuve JP, Huet PM, Joly JG, Marleau D, Côté J, Légaré A, Lafortune M, et al. Idiopathic portal hypertension. Am J Med 1976; 61: 459-64.

  41. Sama SK, Bhargava S, Nath NG, Talwar JR, Nayak NC, Tandon BN, Wig KL. Noncirrhotic portal fibrosis. Am J Med 1971; 51: 160-9.

  42. Degott C, Capron JP, Bettan L, Molas G, Bernuau D, Potet F, Feldmann G, et al. Myeloid metaplasia, perisinusoidal fibrosis, and nodular regenerative hyperplasia of the liver. Liver 1985; 5: 276-81.

  43. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, Binda T, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94: 1063-9.




2020     |     www.medigraphic.com